Global Artificial Intelligence in Drug Discovery
Market Report
2024
Artificial Intelligence in Drug Discovery market size is USD 815.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 40.00% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Artificial Intelligence in Drug Discovery Market Report 2024.
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size is USD 815.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 40.00% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Artificial Intelligence in Drug Discovery Market Sales Revenue 2024 | $ 815.2 Million |
Global Artificial Intelligence in Drug Discovery Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 40% |
North America Artificial Intelligence in Drug Discovery Sales Revenue 2024 | $ 326.08 Million |
North America Artificial Intelligence in Drug Discovery Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 38.2% |
Europe Artificial Intelligence in Drug Discovery Sales Revenue 2024 | $ 244.56 Million |
Europe Artificial Intelligence in Drug Discovery Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 38.5% |
Asia Pacific Artificial Intelligence in Drug Discovery Sales Revenue 2024 | $ 187.5 Million |
Asia Pacific Artificial Intelligence in Drug Discovery Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 42% |
South America Artificial Intelligence in Drug Discovery Sales Revenue 2024 | $ 40.76 Million |
South America Artificial Intelligence in Drug Discovery Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 39.4% |
Middle East and Africa Artificial Intelligence in Drug Discovery Sales Revenue 2024 | $ 16.3 Million |
Middle East and Africa Artificial Intelligence in Drug Discovery Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 39.7% |
Market Split by Technology |
|
Market Split by Offering |
|
Market Split by Therapeutic Area |
|
Market Split by Process |
|
Market Split by Use Cases |
|
Market Split by End-User |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Artificial Intelligence in Drug Discovery industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Artificial Intelligence in Drug Discovery Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Artificial intelligence in the drug discovery market addresses the convergence of Artificial intelligence advancements and drug research, planning to speed up and improve the medication disclosure and advancement process. Computer-based intelligence offers extraordinary capacities in examining immense measures of organic and compound information, anticipating sub-atomic communications, and distinguishing potential medication competitors with higher accuracy and effectiveness than customary techniques. Artificial Intelligence (AI) in drug discovery market drivers allude to the elements animating development and reception of simulated intelligence advancements inside the drug business. A few key drivers have pushed the development of computer based intelligence in this area. The rising intricacy and cost of conventional medication revelation strategies have driven drug organizations to look for additional effective arrangements. Computer based intelligence offers the commitment of speeding up the medication revelation process through prescient displaying, virtual screening, and information investigation, in this manner decreasing time and expenses. The dramatic development of accessible biomedical information, including genomics, proteomics, and clinical information, requires progressed computational methods to separate significant experiences. Artificial intelligence succeeds in taking care of and deciphering enormous datasets, giving significant help with distinguishing potential drug applicants and grasping illness components. Also, administrative organizations are progressively perceiving and empowering the combination of artificial intelligence advancements in drug improvement, working with smoother endorsement processes for artificial intelligence-driven drug disclosure devices and procedures. The examples of overcoming adversity and showing the viability of artificial intelligence applications in drug disclosure stand out enough to be noticed and speculated by both drug organizations and financial speculators, further driving the development of this market. In outline, the combination of mechanical headways, information overflow, administrative help, and market request altogether act as the market drivers moving the reception of artificial intelligence in drug disclosure.
In October 2023, Recursion, in collaboration with Roche and Genentech, achieved its first significant milestone by identifying and validating a hit series for a specific disease, prompting Roche's Small Molecule Validation Program Option.
(Source: https://www.recursion.com/news/an-exciting-milestone-in-our-partnership-with-roche-and-genentech)
Customised medication, fitting medicines to individual patients in the opinion of their hereditary cosmetics and different elements, is picking up speed because of its capability to develop results further and limit unfavorable impacts. Simulated intelligence assumes an urgent role in this change in outlook by dissecting tremendous datasets enveloping genomics, proteomics, and clinical records. AI calculations filter through this information to recognize examples and connections, supporting the revelation of biomarkers for sickness inference and guessing. Regular language handling empowers the abstraction of significant experiences from unstructured clinical notes and examination writing. By utilizing computer-based intelligence, specialists can foster designated treatments that address the particular sub-atomic qualities of a patient's illness, improving treatment viability and patient outcomes in a period progressively centered around customized medical services.
Conventional medication discovery faces difficulties originating from the difficulty of illnesses, high disappointment rates in clinical preliminaries, and rising improvement costs. Simulated intelligence offers inventive answers to assist different phases of medication advancement by outfitting the force of computational calculations and huge information investigation. AI calculations break down different datasets, for example, genomic successions and compound designs, to anticipate drug-target collaborations and distinguish promising competitors. Besides, artificial intelligence-driven models smooth out lead streamlining and harmfulness expectations, lessening the time and assets expected for preclinical testing. By speeding up the speed of medication disclosure and advancing asset assignment, artificial intelligence advancements moderate dangers and improve the productivity of medication improvement.
One critical limitation in the Man-made reasoning in the medication discovery market is the test of accomplishing adequate brilliance and picture quality in conservative and compact gadgets. Because of their small size and appreciative power sources, Man-made consciousness in Medication Revelation frequently battles to convey a similar degree of splendor and picture lucidity as bigger, fixed projectors. This impediment can obstruct their viability in brilliantly lit conditions or while projecting onto bigger screens, lessening their common sense for specific applications like proficient introductions or outside occasions. While progressions in Drove and laser projection innovation have further developed brilliance levels in Man-made brainpower in Medication Disclosure, accomplishing great pictures without compromising versatility remains a critical test for makers.
The Covid pandemic has intriguingly worked on gathering AI in drug discovery. With the basic need to encourage convincing meds and vaccinations for the original Coronavirus, scientists have gone to recreated knowledge to add to the drug progression process. Man-made brainpower-driven computations enable the quick assessment of enormous proportions of biomedical data, including genomic groupings, protein structures, and clinical primer data, to perceive potential medicine contenders and expect their practicality. Also, reenacted insight-controlled virtual screening and sub-nuclear showing strategies have worked with the distinctive verification of reused prescriptions and novel supportive concentrations for COVID-19. The pandemic has featured the meaning of using recreated knowledge's perceptive capacities and computational capacity to accelerate drug divulgence attempts, provoking extended adventure and gathering of reenacted insight progressions in the medication business. Consequently, the COVID crisis has filled in as an impulse for the turn of events and advancement of Artificial reasoning in drug exposure, with strong repercussions for the clinical benefits scene.
We have various report editions of Artificial Intelligence in Drug Discovery Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The artificial intelligence in the medication discovery market is exceptionally cutthroat, with vital participants like Insilico Medication, BenevolentAI, and Atomwise viewing for a piece of the pie. These organizations influence progressed computer-based intelligence calculations and huge information investigation to speed up drug revelation processes, offering answers for target distinguishing proof, lead enhancement, and prescient displaying. Cooperation with drug organizations and examination establishments further strengthens the contest in this quickly advancing business sector
Top Companies Market Share in Artificial Intelligence in Drug Discovery Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. North America dominates the AI drug discovery market because of its hearty medical care framework, huge interest in artificial intelligence innovative work, presence of driving drug organizations, and steady administrative climate. Moreover, the district benefits from areas of strength for scholastic and exploration establishments cultivating development in artificial intelligence-driven drug revelation advances.
Asia-Pacific stands out as the fastest-growing region in the Artificial Intelligence in Drug Discovery market due to several compelling reasons. The region has a quickly extending drug industry, expanding interests in artificial intelligence advances, and a developing accentuation on innovative work. Moreover, ideal government strategies, rising medical care consumption, and an enormous pool of gifted abilities add to the locale's sped-up reception of computer-based intelligence in drug revelation. Besides, coordinated efforts between drug organizations, scholastic foundations, and innovation firms further drive development and impel the development of the market in Asia Pacific
The current report Scope analyzes Artificial Intelligence in Drug Discovery Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size was estimated at USD 815.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 326.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 38.2% from 2024 to 2031. In North America, artificial intelligence in the Drug Discovery market displays a promising situation energized by its high-level medical services foundation and gigantic interests in Research and development. The strength of the area as far as advancement and mechanical improvement goes about as a main thrust. Division examination features the notoriety of different clinical fields like oncology, irresistible illnesses, rheumatology, interior medication, cardiology, immunology, and other clinical fields Oncology tops because of disease predominance and dire interest for leading-edge treatments for different kinds of disease are arising as a quickly developing fragment, tending to immune system problems and other immunological. All in all, North American artificial intelligence in the Drug Discovery market holds an extraordinary commitment to development, highlighted by an exhaustive way to deal with addressing clinical requirements and utilizing innovations to further develop medical care.
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size was estimated at USD 815.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 244.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 38.5% from 2024 to 2031. In Europe, Artificial intelligence in the Drug Discovery market shows a recognizable commitment to expanding the center around leading the board. The locale's solid drug industry and expanding reception of trend-setting innovations are driving the market development. The division examination further features the acknowledgment of Hit ID and Prioritization as a quickly developing fragment, taking care of developing exploration needs. Hit Recognizable Proof and Prioritization is quite possibly the quickest developing region in Europe, because of its critical job in accelerating the arrangement disclosure process and further developing productivity. With an emphasis on fast and precise distinguishing proof of potential Drug Discovery, this fragment partakes in the capacity to further develop research effectiveness and limit misuse of assets. All in all, the European artificial intelligence in the Medication Revelation market addresses a powerful fragment that is ready for development, driven by progress in leading the board and the developing significance of Hit Distinguishing proof and Prioritization.
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size was estimated at USD 815.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 187.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 42.0% from 2024 to 2031. In the Asia Pacific locale, artificial intelligence in the Drug Discovery market shows a promising scene portrayed by the rising reception of artificial intelligence-driven arrangements by drug and biotechnology organizations. The driving variable for the market in the district is the developing interest in imaginative medication disclosure answers to address neglected clinical requirements. Division examination further features the notoriety of AI, normal language handling, setting mindful handling, programming, and administrations in the district, and taking special care of various customer inclinations and necessities. Drug and biotechnology organizations rule the market because of their significant interest in innovative work, combined with their emphasis on advancement and new drug discovery pipelines. All in all, the Asia Pacific district presents a blossoming market for artificial intelligence in Drug Discovery, driven by major areas of strength for the drug and biotechnology organizations and the developing accentuation on development in drug improvement processes.
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size was estimated at USD 815.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 40.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 39.4% from 2024 to 2031. In Latin America, artificial intelligence in the Drug Discovery market shows a promising scene portrayed by the developing reception of innovation-driven arrangements. AI and regular language handling are especially noticeable, driven by the district's rising spotlight on improving medication disclosure processes. Division examination further features the prominence of administrations over programming in Latin America, taking care of the particular necessities and prerequisites of drug and biotechnology organizations, research focuses, and scholastic establishments. Administrations overwhelm because of their adjustable nature and capacity to give fitted answers to clients. All in all, Latin America's artificial intelligence in the Drug Discovery market exhibits areas of strength for administration contributions, upheld by the locale's accentuation on customized and adaptable answers to address the intricacies of medication disclosure processes.
According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size was estimated at USD 815.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 16.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 39.7% from 2024 to 2031. In the Middle East, the AI in Drug Discovery market exhibits a promising landscape characterized by the increasing adoption of Natural Language Processing (NLP). The driving element for the market in the district is the developing requirement for cutting-edge language handling capacities to break down huge measures of biomedical information productively. Division examination further features the notoriety of AI, NLP, Setting mindful Handling, and Different Advances in the district, taking care of purchaser inclinations and necessities. AI overwhelms us because of its flexibility and viability in recognizing examples and making expectations from complex datasets. All in all, Center East's artificial intelligence in the Medication Revelation market is ready for critical development driven by the rising usage of Normal Language Handling and the strength of AI in tending to the area's medical care difficulties.
Global Artificial Intelligence in Drug Discovery Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Artificial Intelligence in Drug Discovery Industry growth. Artificial Intelligence in Drug Discovery market has been segmented with the help of its Technology, Offering Therapeutic Area, and others. Artificial Intelligence in Drug Discovery market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, Natural Language Processing is the dominating category of Artificial Intelligence in the Drug Discovery market. Natural Language Processing (NLP) is critical in drug disclosure as it empowers the examination of huge measures of unstructured information, for example, logical writing and clinical preliminary reports. By removing significant bits of knowledge from text-based information, NLP works with the distinguishing proof of potential medication targets, biomarkers, and remedial pathways, in this way upgrading the effectiveness and precision of the medication disclosure process.
Machine Learning emerges as the fastest-growing category in Artificial Intelligence in the Drug Discovery market. The fast development of AI can be ascribed to its capacity to dissect complex organic information and foresee sub-atomic connections, drug viability, and harmfulness with high precision. AI calculations consistently work on their presentation as they process more information, making them significant instruments for drug disclosure research. Also, headways in computational power and calculation advancement have energized the reception of AI in drug revelation, driving its quick development on the lookout.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Artificial Intelligence in Drug Discovery Industry. Request a Free Sample PDF!
According to Cognitive Market Research, services stand out as the dominating category in Artificial Intelligence in the Drug Discovery market. Services encompass a wide range of offerings, for example, counseling, execution, and upkeep, offering complete help to drug and biotechnology organizations in utilizing computer-based intelligence advancements for drug revelation. This predominance is driven by the rising interest in particular aptitude and custom-made answers for exploring the intricacies of artificial intelligence-driven drug advancement processes.
The fastest-growing category in the Artificial Intelligence in Drug Discovery market is software. The rapid growth of software offerings is fueled by progressions in AI calculations and normal language handling apparatuses, empowering more productive and exact examination of enormous datasets. Furthermore, the versatility and adaptability of programming arrangements appeal to an expansive range of end-clients, working with consistent combinations into existing work processes and driving reception across the drug and biotechnology areas.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Artificial Intelligence in Drug Discovery market report 2024 Edition by contacting our team.
According to Cognitive Market Research, the dominating category is the oncology therapeutic area. Oncology dominates due to the significant prevalence of cancer worldwide, driving extensive research efforts and investment in drug discovery within this therapeutic area. The intricacy of cancer biology and the critical requirement for additional powerful medicines further accentuate the significance of computer-based intelligence-driven headways in oncology drug revelation. With artificial intelligence's capacity to break down huge measures of information and distinguish potential medication competitors, it turns into an important apparatus in speeding up the improvement of novel oncology therapeutics.
The fastest-growing category in the Artificial Intelligence in Drug Discovery market is Immunology therapeutic areas. The fast development is powered by the rising comprehension of the safe framework's job in different sicknesses, including immune system problems, irresistible illnesses, and diseases. Artificial intelligence works with the recognizable proof of novel restorative targets and the plan of immunomodulatory drugs, prompting creative therapy draws near and tending to neglected clinical necessities in immunology. This uplifted spotlight on immunotherapy, combined with artificial intelligence's capacities to smooth out drug revelation processes, drives the sped-up development of artificial intelligence applications in this helpful region.
According to Cognitive Market Research, lead optimization stands out as the dominating category in the Process segment of Artificial Intelligence in the Drug Discovery market. Lead optimization is essential in drug advancement as it includes refining potential medication contender to upgrade their adequacy, well-being, and pharmacological properties. It requires complex calculations and computational models, making it an essential part where artificial intelligence innovations like AI succeed, consequently laying out lead streamlining as the overwhelming section.
Hit Identification & Prioritization emerges as the fastest-growing category in the Artificial Intelligence in Drug Discovery market. This segment's quick development can be ascribed to its basic job in the beginning phases of medication disclosure, where artificial intelligence-driven calculations filter through huge datasets to distinguish promising medication targets effectively. With the rising reception of artificial intelligence advancements and the developing interest in novel therapeutics, the hit ID and prioritization fragment encounters sped up development because of its capacity to assist the medication disclosure process and diminish costs.
According to Cognitive Market Research, Small Molecule Design and Optimization stands out as the dominating category in Artificial Intelligence in the Drug Discovery market. Small molecules stay the foundation of drug mediations because of their capacity to target explicit organic pathways with accuracy, frequently bringing about powerful helpful impacts. AI calculations succeed in examining huge compound datasets, foreseeing atomic properties, and planning upgraded little particles with wanted pharmacological profiles. Their boundless reception by drug organizations and exploration foundations highlights the predominance of little particle plans and improvement in artificial intelligence-driven drug revelation endeavors.
Vaccine Design and Optimization emerges as the fastest-growing category in the Artificial Intelligence in Drug Discovery market. The quick development in this section can be credited to a few variables. Right off the bat, the squeezing need for novel immunizations, featured by late worldwide well-being emergencies, has prodded escalated innovative work endeavors in antibody plans. Besides, headways in computational science and AI strategies have engaged analysts to speed up the antibody advancement process by anticipating antigenic epitopes, streamlining immunization plans, and surveying immunogenicity profiles. Besides, the adaptability and cost-adequacy of artificial intelligence-driven approaches in antibody advancement further fuel the quick development of this section, as partners look for creative answers for battle arising irresistible illnesses and address neglected clinical necessities.
According to Cognitive Market Research, Pharmaceutical & Biotechnology Companies stand out as the dominating category in the Artificial Intelligence in Drug Discovery market. Pharmaceutical and biotechnology associations have been early adopters of man-made consciousness progressions in drug revelation on account of their tremendous resources, research limits, and the pressing need to streamline the medicine improvement process. These organizations influence artificial intelligence to improve proficiency in target recognizable proof, lead streamlining, and clinical preliminary plans, prompting quicker and more practical medication disclosure pipelines. Moreover, the rising intricacy of sicknesses and the interest in customized medication further drive the reception of artificial intelligence among drug and biotechnology organizations.
Contract Research Organizations emerge as the fastest-growing category in the Artificial Intelligence in Drug Discovery market. Contract Research Organizations (CROs) are seeing quick development because of their specific ability, adaptability, and cost-adequacy in giving artificial intelligence-driven drug disclosure administrations. CROs offer tailored answers for drug and biotechnology organizations, assisting them with utilizing Artificial intelligence advancements without critical forthright interests in foundation and ability. Additionally, the developing pattern of re-appropriating drug disclosure exercises, combined with the rising interest in artificial intelligence-driven arrangements, powers the extension of the CRO market. This permits drug organizations to zero in on center skills while utilizing the particular capacities of CROs to speed up drug disclosure processes.
Research associate at Cognitive Market Research
Swasti Dharmadhikari, an agile and achievement-focused market researcher with an innate ardor for deciphering the intricacies of the Service & Software sector. Backed by a profound insight into technology trends and consumer dynamics, she has committed herself to meticulously navigating the ever-evolving terrain of digital Services and software solutions.
As a research analyst, Swasti brings a unique blend of analytical prowess and strategic thinking to the table. With an expertise in market research analysis, She is adept at dissecting complex problems, extracting meaningful insights, and translating them into actionable recommendations. Her passion lies in leveraging data-driven approaches to guide decision-making and drive organizational success.
I played a central role in market research endeavors and competitive analysis. I have a demonstrated ability to leverage diverse data sources, employing advanced analytics tools to discern patterns and trends. My collaborative approach facilitated effective communication of insights, fostering a culture of data-driven decision-making within the organization. I am committed to continuous professional development, actively seeking opportunities for skill enhancement through workshops, industry conferences, and staying abreast of emerging trends in research methodologies.
Disclaimer:
Technology | Machine Learning, Natural Language Processing, Context-aware Processing, Other Technologies |
Offering | Software, Services |
Therapeutic Area | Oncology, Infectious Diseases, Neurology, Metabolic Diseases, Cardiovascular Diseases, Immunology, Other Therapeutic Areas |
Process | Target Identification & Selection, Target Validation, Hit Identification & Prioritization, Hit-to-lead Identification/ Lead generation, Lead Optimization, Candidate Selection & Validation |
Use Cases | Understanding Disease, Small Molecule Design and Optimization, Vaccine Design and Optimization, Antibody & Other Biologics Design and Optimization, Safety and Toxicity |
End-User | Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Research Centers and Academic & Government Institutes |
List of Competitors | NVIDIA Corporation (U.S.), Cyclica (Canada), NuMedii, Inc. (U.S.), Envisagenics (U.S.), Owkin Inc. (U.S.), BERG LLC (U.S.), Schrödinger Inc(U.S.), XtalPi Inc (China), IBM(U.S.), Atomwise Inc. (U.S.), Microsoft (U.S.), Benevolent AI (U.K.), Aria PharmaceuticalsInc(U.S.), DEEP GENOMICS (Canada), Exscientia (U.K.), Insilico Medicine (U.S.) |
This chapter will help you gain GLOBAL Market Analysis of Artificial Intelligence in Drug Discovery. Further deep in this chapter, you will be able to review Global Artificial Intelligence in Drug Discovery Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Chapter 2 North America Market Analysis
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Artificial Intelligence in Drug Discovery Market Trends North America Artificial Intelligence in Drug Discovery Technological Road Map North America Artificial Intelligence in Drug Discovery Market Drivers North America Artificial Intelligence in Drug Discovery Market Restraints North America Artificial Intelligence in Drug Discovery Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
Chapter 3 Europe Market Analysis
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
Chapter 4 Asia-Pacific Market Analysis
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
Chapter 5 South America Market Analysis
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
Chapter 6 Middle East and Africa Market Analysis
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Technology Analysis 2019 -2031, will provide market size split by Technology. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Technology Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Offering Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Therapeutic Area Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Process Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by Use Cases Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 15 Market Split by End-User Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Artificial Intelligence in Drug Discovery market
Chapter 16 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Machine Learning have a significant impact on Artificial Intelligence in Drug Discovery market? |
What are the key factors affecting the Machine Learning and Natural Language Processing of Artificial Intelligence in Drug Discovery Market? |
What is the CAGR/Growth Rate of Software during the forecast period? |
By type, which segment accounted for largest share of the global Artificial Intelligence in Drug Discovery Market? |
Which region is expected to dominate the global Artificial Intelligence in Drug Discovery Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Artificial Intelligence in Drug Discovery Market
Request Sample